Senseonics Holdings, Inc. (SENS)
| Market Cap | 300.15M |
| Revenue (ttm) | 35.26M |
| Net Income (ttm) | -69.11M |
| Shares Out | 41.80M |
| EPS (ttm) | -1.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,586 |
| Open | 7.23 |
| Previous Close | 7.27 |
| Day's Range | 7.14 - 7.45 |
| 52-Week Range | 5.25 - 15.62 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 18.38 (+155.99%) |
| Earnings Date | May 8, 2026 |
About SENS
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company ser... [Read more]
Financial Performance
In 2025, Senseonics Holdings's revenue was $35.26 million, an increase of 56.89% compared to the previous year's $22.47 million. Losses were -$69.11 million, -12.09% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SENS stock is "Strong Buy." The 12-month stock price target is $18.38, which is an increase of 155.99% from the latest price.
News
Senseonics Announces European Launch of Eversense® 365, The World's First and Only One Year CGM System
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out
First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear
New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes
Senseonics Holdings Earnings Call Transcript: Q4 2025
Revenue grew 60% year-over-year to $35.3M in 2025, with gross margin exceeding 50% and patient base doubling in the U.S. The company expects 2026 revenue of $58–$62M, driven by European expansion, new product launches, and continued DTC investment.
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration,...
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is w...
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is w...
Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuo...
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM
Senseonics Holdings Transcript: Stifel 2025 Healthcare Conference
A 365-day CGM sensor is driving a shift to a direct sales model in 2026, expected to boost revenue and margins. DTC campaigns and a growing nurse network are fueling rapid patient growth, while new products and pump integrations expand future opportunities.
Senseonics Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw 90% revenue growth, record new patient starts, and margin expansion driven by Eversense 365 adoption and DTC marketing. Commercialization transition from Ascensia is on track, with 2025 revenue guidance at $35M and gross margins set to rise further.
Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17...
Senseonics Holdings Transcript: Status Update
Eversense 365 commercialization will transition in-house by 2026, ending the Ascensia partnership and enabling higher margins, direct investment, and unified control. Strong growth momentum continues, with record patient starts and expanded DTC efforts, while financial guidance and funding outlook remain robust.
Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics
TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today...
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Herc...
Senseonics Holdings Earnings Call Transcript: Q2 2025
Q2 revenue grew 37% year-over-year to $6.6M, driven by Eversense 365 adoption and expanded DTC marketing. Net loss narrowed to $14.5M, and full-year revenue is guided at $34–38M with gross margin of 32.5–37.5%. Cash position strengthened to $126.7M.
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Se...
Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes
GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Holdings Earnings Call Transcript: Q1 2025
Eversense 365 CGM launch and integration with Sequel's Twist pump drove 24% revenue growth in Q1 2025, with strong U.S. adoption and rapid payer transitions. 2025 guidance is reiterated, targeting $34–38 million in revenue and a doubling of the global patient base.
Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable...
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system